Pancreatic Cancer Research

ResearcherAffiliated Hospital of Guizhou Medical UniversityNo recent work listed

Haitao Zhu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1435-9607; OpenAlex author ID A5101893204. Sources: OpenAlex.

Their work

Papers
4 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2018: 2 papers · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper

Papers 4

  1. LHPP suppresses proliferation, migration, and invasion in hepatocellular carcinoma and pancreatic cancer by inhibiting EGFR signaling pathway. Co-author DOI 10.1007/s12032-023-02127-1↗
  2. E2F2 enhances the chemoresistance of pancreatic cancer to gemcitabine by regulating the cell cycle and upregulating the expression of RRM2. Last author DOI 10.1007/s12032-022-01715-x↗
  3. MiR-1297 suppresses pancreatic cancer cell proliferation and metastasis by targeting MTDH. Co-author DOI 10.1016/j.mcp.2018.06.003↗
  4. Combination of gemcitabine and erlotinib inhibits recurrent pancreatic cancer growth in mice via the JAK-STAT pathway. Co-author DOI 10.3892/or.2018.6198↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qianfan Liu · 3 shared papers, 2018–2023 · strength 0.46
  2. Liyue Fu · 1 shared paper, 2023 · strength 0.22
  3. Zili Chen · 2 shared papers, 2018 · strength 0.18
  4. Chengyi Sun · 2 shared papers, 2018 · strength 0.18
  5. Zhirui Zeng · 1 shared paper, 2022 · strength 0.16
  6. Chao Yu · 1 shared paper, 2018 · strength 0.10
  7. Yaozhen Pan · 1 shared paper, 2018 · strength 0.10
  8. Liwen Chen · 1 shared paper, 2018 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.